Literature DB >> 9819830

A Markov mixed effect regression model for drug compliance.

P Girard1, T F Blaschke, H Kastrissios, L B Sheiner.   

Abstract

Patient compliance (adherence) with prescribed medication is often erratic, while clinical outcomes are causally linked to actual, rather than nominal medication dosage. We propose here a hierarchical Markov model for patient compliance. At the first stage, conditional upon individual random effects and a set of individual-specific nominal daily dose times, we assume that (i) the subject-specific probability of taking zero, one, or more than one dose associated with a given nominal dose time depends on the value of certain covariates, and on the number of doses associated with the immediate previous time, but is independent of any other previous or future dosing events (the Markov hypothesis); and (ii) the set of 'errors' between actual dose times associated with each nominal time is multivariate normally distributed, conditional on covariates and the number of such actual dose times, as in (i). At the second stage, a multivariate normal distribution is assumed for the individual random effects. We fit this model by maximum likelihood to data collected over three months using an electronic system for recording actual dose times in HIV-positive patients assigned to a regimen of zidovudine thrice daily. Beyond its value for describing and quantifying compliance behaviour, as illustrated here, the model may prove useful for explanatory analyses of clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819830     DOI: 10.1002/(sici)1097-0258(19981030)17:20<2313::aid-sim935>3.0.co;2-v

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  34 in total

1.  A brief introduction to Monte Carlo simulation.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Bayesian population modeling of drug dosing adherence.

Authors:  Kelly Fellows; Colin J Stoneking; Murali Ramanathan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-29       Impact factor: 2.745

5.  The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.

Authors:  Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
Journal:  AAPS J       Date:  2004-08-11       Impact factor: 4.009

Review 6.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 7.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

8.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

9.  Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists.

Authors:  Alexia Blesius; Sylvie Chabaud; Michel Cucherat; Patrick Mismetti; Jean-Pierre Boissel; Patrice Nony
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  Assessment of Markov-dependent stochastic models for drug administration compliance.

Authors:  Diane Wong; Reshma Modi; Murali Ramanathan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.